{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:28:25Z","timestamp":1777951705395,"version":"3.51.4"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"19","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160329"],"award-info":[{"award-number":["82160329"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths globally.\nTraditional treatments face limitations like low effectiveness, poor specificity, and significant side effects.\nGene therapy, particularly siRNA-based, is promising for targeted gene regulation but requires effective delivery\nsystems due to the instability and poor target delivery of unmodified siRNA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study examined the storage and biological stability of LP-PEI-SPION (LPS) and GPC3-LPPEI-\nSPION (GLPS). The potential of these agents as tumor imaging contrast agents and the targeting ability\nof gene delivery carriers were assessed through ex vivo organ fluorescence imaging and in vivo tumor magnetic\nresonance imaging (MRI). Antitumor efficacy was evaluated through tumor volume, protein blotting, immunohistochemistry,\nand TUNEL assays. In vivo safety was evaluated using HE staining, nude mouse weight\nchanges, and blood biochemical indicators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>LPS and GLPS both formed stable siRNA complexes. GLPS showed excellent tumor targeting in\nvivo. MRI results showed that the GPC3-targeting peptide effectively enhanced the MR imaging performance\nand diagnostic accuracy. Tumor volume and weight measurements demonstrated potent tumor inhibition by\nGLPS\/siRNA. Immunoblotting and immunohistochemistry revealed significant GPC3 reduction in the GLPS\/\nsiRNA-targeted group. Safety evaluations confirmed good biocompatibility for both LPS\/siRNA and GLPS\/\nsiRNA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>GLPS\/siRNA demonstrates good stability, tumor targeting, imaging capability, and antitumor\nefficacy with favorable safety, positioning it as a promising theragnostic platform for HCC. This integrated\nsystem provides novel clinical tools for diagnosis and treatment, establishes a foundation for clinical translation,\nand enables simultaneous tumor imaging and gene therapy\u2014offering innovative strategies for combined\ntumor theranostics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113816128395585250923122829","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T12:31:21Z","timestamp":1760790681000},"page":"1524-1535","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research on Anti-tumor Pharmacodynamics of Multi-functional Magnetic Lipid Polymer with Specific Targeted Transmission of siRNA and its Toxicity Evaluation"],"prefix":"10.2174","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0315-1342","authenticated-orcid":true,"given":"Yaru","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Radiology, Yanbian University Hospital, Yanji, 133000, Jilin Province, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4658-6870","authenticated-orcid":true,"given":"Chang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Yanbian University Hospital, Yanji, 133000, Jilin Province, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"Spine Surgery, Yanbian University Hospital, Yanji, 133000, Jilin Province, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jishan","family":"Quan","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Yanbian University, Yanji, 133000, JilinProvince, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyu","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Radiology, Yanbian University Hospital, Yanji, 133000, Jilin Province, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"Siegel R.L.","year":"2022","unstructured":"Siegel R.L.; Miller K.D.; Fuchs H.E.; Jemal A.; Cancer statistics, 2022. CA Cancer J Clin  2022,72(1),7-33","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H.","year":"2021","unstructured":"Sung H.; Ferlay J.; Siegel R.L.; Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2021,71(3),209-249","journal-title":"CA Cancer J Clin"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.6004\/jnccn.2017.0059","volume":"15","author":"Benson A.B.","year":"2017","unstructured":"Benson A.B.; D\u2019Angelica M.I.; Abbott D.E.; NCCN guidelines insights: Hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw  2017,15(5),563-573","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"Vogel A.","year":"2022","unstructured":"Vogel A.; Meyer T.; Sapisochin G.; Salem R.; Saborowski A.; Hepatocellular carcinoma. Lancet  2022,400(10360),1345-1362","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"Yang J.D.","year":"2019","unstructured":"Yang J.D.; Hainaut P.; Gores G.J.; Amadou A.; Plymoth A.; Roberts L.R.; A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol  2019,16(10),589-604","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"Park J.W.","year":"2015","unstructured":"Park J.W.; Chen M.; Colombo M.; Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study. Liver Int  2015,35(9),2155-2166","journal-title":"Liver Int"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1097\/SLA.0000000000001556","volume":"263","author":"Dhir M.","year":"2016","unstructured":"Dhir M.; Melin A.A.; Douaiher J.; A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg  2016,263(6),1112-1125","journal-title":"Ann Surg"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3350\/cmh.2023.0106","volume":"29","author":"Yang T.","year":"2023","unstructured":"Yang T.; Wang M.D.; Xu X.F.; Li C.; Wu H.; Shen F.; Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences. Clin Mol Hepatol  2023,29(2),342-344","journal-title":"Clin Mol Hepatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.3390\/cancers14112798","volume":"14","author":"Chakraborty E.","year":"2022","unstructured":"Chakraborty E.; Sarkar D.; Emerging therapies for hepatocellular carcinoma (HCC). Cancers  2022,14(11),2798","journal-title":"Cancers"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2400904","DOI":"10.1002\/smtd.202400904","volume":"9","author":"Chen J.","year":"2025","unstructured":"Chen J.; Li S.; Zhou Q.; Near-infrared II fluorescence imaging highlights tumor angiogenesis in hepatocellular carcinoma with a VEGFR\u2010targeted probe. Small Methods  2025,9(3),2400904","journal-title":"Small Methods"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1002\/jgm.3550","volume":"25","author":"Cesur-Erg\u00fcn B.","year":"2023","unstructured":"Cesur-Erg\u00fcn B.; Demir-Dora D.; Gene therapy in cancer. J Gene Med  2023,25(11),3550","journal-title":"J Gene Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3390\/cancers11121865","volume":"11","author":"Kamimura K.","year":"2019","unstructured":"Kamimura K.; Yokoo T.; Abe H.; Terai S.; Gene therapy for liver cancers: Current status from basic to clinics. Cancers  2019,11(12),1865","journal-title":"Cancers"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.7150\/thno.102964","volume":"15","author":"Yuan Y.","year":"2025","unstructured":"Yuan Y.; Sun W.; Xie J.; RNA nanotherapeutics for hepatocellular carcinoma treatment. Theranostics  2025,15(3),965-992","journal-title":"Theranostics"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1527600","DOI":"10.3389\/fmed.2024.1527600","volume":"11","author":"Youssef E.","year":"2025","unstructured":"Youssef E.; Fletcher B.; Palmer D.; Enhancing precision in cancer treatment: The role of gene therapy and immune modulation in oncology. Front Med  2025,11,1527600","journal-title":"Front Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/17425247.2025.2484287","volume":"22","author":"Weiskirchen R.","year":"2025","unstructured":"Weiskirchen R.; Weiskirchen S.; Grassi C.; Recent advances in optimizing siRNA delivery to hepatocellular carcinoma cells. Expert Opin Drug Deliv  2025,22(5),729-745","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/PGPM.S431346","volume":"17","author":"Younis M.","year":"2024","unstructured":"Younis M.; Harashima H.; Understanding gene involvement in hepatocellular carcinoma: Implications for gene therapy and personalized medicine. Pharm Genomics Pers Med  2024,17,193-213","journal-title":"Pharm Genomics Pers Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"155509","DOI":"10.1016\/j.prp.2024.155509","volume":"261","author":"Mohd Abas M.D.","year":"2024","unstructured":"Mohd Abas M.D.; Mohd Asri M.F.; Yusafawi N.A.S.; Advancements of gene therapy in cancer treatment: A comprehensive review. Pathol Res Pract  2024,261,155509","journal-title":"Pathol Res Pract"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2312153","DOI":"10.1002\/smll.202312153","volume":"20","author":"Luo R.","year":"2024","unstructured":"Luo R.; Le H.; Wu Q.; Gong C.; Nanoplatform\u2010based in vivo gene delivery systems for cancer therapy. Small  2024,20(30),2312153","journal-title":"Small"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"Elbashir S.M.","year":"2001","unstructured":"Elbashir S.M.; Harborth J.; Lendeckel W.; Yalcin A.; Weber K.; Tuschl T.; Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature  2001,411(6836),494-498","journal-title":"Nature"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"Fire A.","year":"1998","unstructured":"Fire A.; Xu S.; Montgomery M.K.; Kostas S.A.; Driver S.E.; Mello C.C.; Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature  1998,391(6669),806-811","journal-title":"Nature"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"Setten R.L.","year":"2019","unstructured":"Setten R.L.; Rossi J.J.; Han S.; The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov  2019,18(6),421-446","journal-title":"Nat Rev Drug Discov"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/hep.20702","volume":"41","author":"Morrissey D.V.","year":"2005","unstructured":"Morrissey D.V.; Blanchard K.; Shaw L.; Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology  2005,41(6),1349-1356","journal-title":"Hepatology"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev-chembioeng-061010-114133","volume":"2","author":"Whitehead K.A.","year":"2011","unstructured":"Whitehead K.A.; Dahlman J.E.; Langer R.S.; Anderson D.G.; Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng  2011,2(1),77-96","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt.3802","volume":"35","author":"Dowdy S.F.","year":"2017","unstructured":"Dowdy S.F.; Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol  2017,35(3),222-229","journal-title":"Nat Biotechnol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"120033","DOI":"10.1016\/j.ijpharm.2020.120033","volume":"592","author":"Song H.","year":"2021","unstructured":"Song H.; Hart S.L.; Du Z.; Assembly strategy of liposome and polymer systems for siRNA delivery. Int J Pharm  2021,592,120033","journal-title":"Int J Pharm"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.15212\/bioi-2022-0028","volume":"4","author":"Tan L.","year":"2023","unstructured":"Tan L.; Wu S.J.; Qiu Y.; Preliminary investigation into ultrasound and MRI presentation of large-cell neuroendocrine carcinomas of the uterine cervix. BIO Integration  2023,4(4),180","journal-title":"BIO Integration"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1038\/s41598-020-60284-z","volume":"10","author":"\u0160ime\u010dkov\u00e1 P.","year":"2020","unstructured":"\u0160ime\u010dkov\u00e1 P.; Hubatka F.; Kotou\u010dek J.; Gadolinium labelled nanoliposomes as the platform for MRI theranostics: In vitro safety study in liver cells and macrophages. Sci Rep  2020,10(1),4780","journal-title":"Sci Rep"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinorgbio.2017.11.025","volume":"180","author":"Skupin-Mrugalska P.","year":"2018","unstructured":"Skupin-Mrugalska P.; Sobotta L.; Warowicka A.; Theranostic liposomes as a bimodal carrier for magnetic resonance imaging contrast agent and photosensitizer. J Inorg Biochem  2018,180,1-14","journal-title":"J Inorg Biochem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1039\/C9TB01834D","volume":"8","author":"Ye S.","year":"2020","unstructured":"Ye S.; Liu Y.; Lu Y.; Cyclic RGD functionalized liposomes targeted to activated platelets for thrombosis dual-mode magnetic resonance imaging. J Mater Chem B Mater Biol Med  2020,8(3),447-453","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/00004424-199005000-00012","volume":"25","author":"Niesman M.R.","year":"1990","unstructured":"Niesman M.R.; Bacic G.G.; Wright S.M.; Swartz H.M.; Magin R.L.; Liposome encapsulated MnCl2 as a liver specific contrast agent for magnetic resonance imaging. Invest Radiol  1990,25(5),545-551","journal-title":"Invest Radiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3390\/nano13132003","volume":"13","author":"Lv J.","year":"2023","unstructured":"Lv J.; Roy S.; Xie M.; Yang X.; Guo B.; Contrast agents of magnetic resonance imaging and future perspective. Nanomaterials  2023,13(13),2003","journal-title":"Nanomaterials"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/ijms17081209","volume":"17","author":"Mart\u00ednez-Gonz\u00e1lez R.","year":"2016","unstructured":"Mart\u00ednez-Gonz\u00e1lez R.; Estelrich J.; Busquets M.; Liposomes loaded with hydrophobic iron oxide nanoparticles: Suitable T2 contrast agents for MRI. Int J Mol Sci  2016,17(8),1209","journal-title":"Int J Mol Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"W302-13","DOI":"10.2214\/AJR.14.12733","volume":"204","author":"Neuwelt A.","year":"2015","unstructured":"Neuwelt A.; Sidhu N.; Hu C.A.A.; Mlady G.; Eberhardt S.C.; Sillerud L.O.; Iron-based superparamagnetic nanoparticle contrast agents for MRI of infection and inflammation. AJR Am J Roentgenol  2015,204(3),W302-13","journal-title":"AJR Am J Roentgenol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40199-015-0124-7","volume":"23","author":"Khalkhali M.","year":"2015","unstructured":"Khalkhali M.; Rostamizadeh K.; Sadighian S.; Khoeini F.; Naghibi M.; Hamidi M.; The impact of polymer coatings on magnetite nanoparticles performance as MRI contrast agents: A comparative study. Daru  2015,23(1),45","journal-title":"Daru"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"502003","DOI":"10.1088\/1361-6528\/ab4241","volume":"30","author":"Wu K.","year":"2019","unstructured":"Wu K.; Su D.; Liu J.; Saha R.; Wang J.P.; Magnetic nanoparticles in nanomedicine: A review of recent advances. Nanotechnology  2019,30(50),502003","journal-title":"Nanotechnology"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.2174\/1381612811319370003","volume":"19","author":"Wang Y.X.","year":"2013","unstructured":"Wang Y.X.; Xuan S.; Port M.; Idee J.M.; Recent advances in superparamagnetic iron oxide nanoparticles for cellular imaging and targeted therapy research. Curr Pharm Des  2013,19(37),6575-6593","journal-title":"Curr Pharm Des"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1517\/17425247.2013.747507","volume":"10","author":"Mok H.","year":"2013","unstructured":"Mok H.; Zhang M.; Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics. Expert Opin Drug Deliv  2013,10(1),73-87","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2174\/138161213804143707","volume":"19","author":"Yoffe S.","year":"2013","unstructured":"Yoffe S.; Leshuk T.; Everett P.; Gu F.; Superparamagnetic iron oxide nanoparticles (SPIONs): Synthesis and surface modification techniques for use with MRI and other biomedical applications. Curr Pharm Des  2013,19(3),493-509","journal-title":"Curr Pharm Des"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/cas.13485","volume":"109","author":"Shimizu Y.","year":"2018","unstructured":"Shimizu Y.; Suzuki T.; Yoshikawa T.; Cancer immunotherapy-targeted glypican-3 or neoantigens. Cancer Sci  2018,109(3),531-541","journal-title":"Cancer Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-22-3895","volume":"83","author":"Schepers E.J.","year":"2023","unstructured":"Schepers E.J.; Glaser K.; Zwolshen H.M.; Hartman S.J.; Bondoc A.J.; Structural and functional impact of posttranslational modification of glypican-3 on liver carcinogenesis. Cancer Res  2023,83(12),1933-1940","journal-title":"Cancer Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3748\/wjg.v22.i1.275","volume":"22","author":"Haruyama Y.","year":"2016","unstructured":"Haruyama Y.; Kataoka H.; Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol  2016,22(1),275-283","journal-title":"World J Gastroenterol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3892\/ol.2018.8754","volume":"16","author":"Wang S.","year":"2018","unstructured":"Wang S.; Chen N.; Chen Y.; Sun L.; Li L.; Liu H.; Elevated GPC3 level promotes cell proliferation in liver cancer. Oncol Lett  2018,16(1),970-976","journal-title":"Oncol Lett"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1039\/C8BM01016A","volume":"7","author":"Zhang Q.","year":"2019","unstructured":"Zhang Q.; Han Z.; Tao J.; An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis. Biomater Sci  2019,7(1),159-167","journal-title":"Biomater Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s13402-017-0364-2","volume":"41","author":"Montalbano M.","year":"2018","unstructured":"Montalbano M.; Rastellini C.; McGuire J.T.; Role of glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma. Cell Oncol  2018,41(2),169-184","journal-title":"Cell Oncol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/cas.14251","volume":"111","author":"Shimizu Y.","year":"2020","unstructured":"Shimizu Y.; Mizuno S.; Fujinami N.; Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Sci  2020,111(2),334-342","journal-title":"Cancer Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/hep.30326","volume":"70","author":"Fu Y.","year":"2019","unstructured":"Fu Y.; Urban D.J.; Nani R.R.; Glypican-3-specific antibody drug conjugates targeting hepatocellular carcinoma. Hepatology  2019,70(2),563-576","journal-title":"Hepatology"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12967-025-06106-0","volume":"23","author":"Zhou M.","year":"2025","unstructured":"Zhou M.; Zhou Z.; Hu L.; Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression. J Transl Med  2025,23(1),88","journal-title":"J Transl Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","volume":"29","author":"Du K.","year":"2021","unstructured":"Du K.; Li Y.; Liu J.; A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Mol Ther  2021,29(4),1572-1584","journal-title":"Mol Ther"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2174\/0113816128258852231204102044","volume":"30","author":"Sun D.","year":"2024","unstructured":"Sun D.; Li X.; Liu Y.; Quan J.; Jin G.; Construction of GPC3-modified Lipopolymer SiRNA Delivery System. Curr Pharm Des  2024,30(19),1507-1518","journal-title":"Curr Pharm Des"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/1567201812666150703114908","volume":"13","author":"Liu H.","year":"2016","unstructured":"Liu H.; Wu D.; In vivo near-infrared fluorescence tumor imaging using dir-loaded nanocarriers. Curr Drug Deliv  2016,13(1),40-48","journal-title":"Curr Drug Deliv"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1021\/acsnano.0c09873","volume":"15","author":"L\u00e1zaro-Ib\u00e1\u00f1ez E.","year":"2021","unstructured":"L\u00e1zaro-Ib\u00e1\u00f1ez E.; Faruqu F.N.; Saleh A.F.; Selection of fluorescent, bioluminescent, and radioactive tracers to accurately reflect extracellular vesicle biodistribution in vivo. ACS Nano  2021,15(2),3212-3227","journal-title":"ACS Nano"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/pharmaceutics14061232","volume":"14","author":"Ao H.","year":"2022","unstructured":"Ao H.; Lu L.; Li M.; Han M.; Guo Y.; Wang X.; Enhanced solubility and antitumor activity of annona squamosa seed oil via nanoparticles stabilized with tpgs: Preparation and in vitro and in vivo evaluation. Pharmaceutics  2022,14(6),1232","journal-title":"Pharmaceutics"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/JHC.S116513","volume":"3","author":"Wu Y.","year":"2016","unstructured":"Wu Y.; Liu H.; Ding H.G.; GPC-3 in hepatocellular carcinoma: Current perspectives. J Hepatocell Carcinoma  2016,3,63-67","journal-title":"J Hepatocell Carcinoma"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.1038\/s41598-020-63465-y","volume":"10","author":"Lazic S.E.","year":"2020","unstructured":"Lazic S.E.; Semenova E.; Williams D.P.; Determining organ weight toxicity with Bayesian causal models: Improving on the analysis of relative organ weights. Sci Rep  2020,10(1),6625","journal-title":"Sci Rep"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.2147\/IJN.S257628","volume":"15","author":"Zhou J.","year":"2020","unstructured":"Zhou J.; Zhou Q.; Shu G.; Dual-effect of magnetic resonance imaging reporter gene in diagnosis and treatment of hepatocellular carcinoma. Int J Nanomedicine  2020,15,7235-7249","journal-title":"Int J Nanomedicine"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1021\/acs.molpharmaceut.4c00917","volume":"22","author":"Sun J.","year":"2025","unstructured":"Sun J.; Jin Z.; Jin Y.; Yuan H.; Jin G.; Quan J.; MRI-based multifunctional nanoliposomes for enhanced hcc therapy and diagnosis. Mol Pharm  2025,22(2),787-807","journal-title":"Mol Pharm"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.2147\/IJN.S191270","volume":"14","author":"Zhang Q.","year":"2019","unstructured":"Zhang Q.; Lu Y.; Xu X.; Li S.; Du Y.; Yu R.; MR molecular imaging of HCC employing a regulated ferritin gene carried by a modified polycation vector. Int J Nanomedicine  2019,14,3189-3201","journal-title":"Int J Nanomedicine"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.2174\/1381612822666161031153159","volume":"23","author":"Arami S.","year":"2017","unstructured":"Arami S.; Mahdavi M.; Rashidi M.R.; Fathi M.; Hejazi M.S.; Samadi N.; Multifunctional superparamagnetic nanoparticles: From synthesis to siRNA delivery. Curr Pharm Des  2017,23(16),2400-2409","journal-title":"Curr Pharm Des"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/mtna.2015.23","volume":"4","author":"Lam J.K.W.","year":"2015","unstructured":"Lam J.K.W.; Chow M.Y.T.; Zhang Y.; Leung S.W.S.; siRNA Versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids  2015,4(9),252","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jconrel.2016.06.011","volume":"244","author":"Lee DJ","year":"2016","unstructured":"Lee DJ; He D; Kessel E; Tumoral gene silencing by receptortargeted combinatorial siRNA polyplexes. J Control Release  2016,244(Pt B),280-91","journal-title":"J Control Release"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1039\/C6SC04293G","volume":"8","author":"Li N.","year":"2017","unstructured":"Li N.; Yang H.; Yu Z.; Nuclear-targeted siRNA delivery for long-term gene silencing. Chem Sci  2017,8(4),2816-2822","journal-title":"Chem Sci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"174178","DOI":"10.1016\/j.ejphar.2021.174178","volume":"905","author":"Alshaer W.","year":"2021","unstructured":"Alshaer W.; Zureigat H.; Al Karaki A.; siRNA: Mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol  2021,905,174178","journal-title":"Eur J Pharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ijpharm.2017.02.032","volume":"525","author":"Barba A.A.","year":"2017","unstructured":"Barba A.A.; Cascone S.; Caccavo D.; Engineering approaches in siRNA delivery. Int J Pharm  2017,525(2),343-358","journal-title":"Int J Pharm"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1903637","DOI":"10.1002\/adma.201903637","volume":"31","author":"Kim B.","year":"2019","unstructured":"Kim B.; Park J.H.; Sailor M.J.; Rekindling RNAi therapy: Materials design requirements for in vivo sirna delivery. Adv Mater  2019,31(49),1903637","journal-title":"Adv Mater"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/nbt.3298","volume":"33","author":"Wittrup A.","year":"2015","unstructured":"Wittrup A.; Ai A.; Liu X.; Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol  2015,33(8),870-876","journal-title":"Nat Biotechnol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nbt.2614","volume":"31","author":"Sahay G.","year":"2013","unstructured":"Sahay G.; Querbes W.; Alabi C.; Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol  2013,31(7),653-658","journal-title":"Nat Biotechnol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.2174\/1381612824666180807121935","volume":"24","author":"Eloy J.O.","year":"2018","unstructured":"Eloy J.O.; Petrilli R.; Raspantini G.L.; Lee R.J.; Targeted liposomes for siRNA delivery to cancer. Curr Pharm Des  2018,24(23),2664-2672","journal-title":"Curr Pharm Des"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.2174\/138161282131151013185850","volume":"21","author":"Vhora I.","year":"2015","unstructured":"Vhora I.; Patil S.; Amrutiya J.; Misra A.; Liposomes and lipid envelope-type systems for systemic siRNA delivery. Curr Pharm Des  2015,21(31),4541-4555","journal-title":"Curr Pharm Des"},{"key":"ref=69","first-page":"36","volume":"36","author":"Wu K.","year":"2024","unstructured":"Wu K.; Wang J.P.; Natekar N.A.; Roadmap on magnetic nanoparticles in nanomedicine. Nanotechnology  2024,36(4),36","journal-title":"Nanotechnology"},{"key":"ref=70","first-page":"437","volume":"9","author":"Balasubramanian S.","year":"2014","unstructured":"Balasubramanian S.; Girija A.R.; Nagaoka Y.; Curcumin and 5-fluorouracil-loaded, folate- and transferrin-decorated polymeric magnetic nanoformulation: A synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia. Int J Nanomedicine  2014,9,437-459","journal-title":"Int J Nanomedicine"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00775-007-0265-3","volume":"12","author":"Frullano L.","year":"2007","unstructured":"Frullano L.; Meade T.J.; Multimodal MRI contrast agents. J Biol Inorg Chem  2007,12(7),939-949","journal-title":"J Biol Inorg Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.addr.2008.03.018","volume":"60","author":"Sun C.","year":"2008","unstructured":"Sun C.; Lee J.S.H.; Zhang M.; Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev  2008,60(11),1252-1265","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"6224","DOI":"10.1039\/D4BM01145G","volume":"12","author":"Luo G.F.","year":"2024","unstructured":"Luo G.F.; Zhang X.Z.; Magnetic nanoparticles for use in bioimaging. Biomater Sci  2024,12(24),6224-6236","journal-title":"Biomater Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1804567","DOI":"10.1002\/adma.201804567","volume":"31","author":"Zhou Z.","year":"2019","unstructured":"Zhou Z.; Yang L.; Gao J.; Chen X.; Structure\u2013relaxivity relationships of magnetic nanoparticles for magnetic resonance imaging. Adv Mater  2019,31(8),1804567","journal-title":"Adv Mater"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1901058","DOI":"10.1002\/adhm.201901058","volume":"9","author":"Farzin A.","year":"2020","unstructured":"Farzin A.; Etesami S.A.; Quint J.; Memic A.; Tamayol A.; Magnetic nanoparticles in cancer therapy and diagnosis. Adv Healthc Mater  2020,9(9),1901058","journal-title":"Adv Healthc Mater"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128395585250923122829","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/246198\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128395585250923122829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:26:10Z","timestamp":1777890370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/246198\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":75,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113816128395585250923122829","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}